China Post-marketing Surveillance (PMS) Study of Aldurazyme®

Inclusion Criteria: * Chinese participants have a documented diagnosis of MPS I confirmed by measurable clinical signs and symptoms of MPS I and fibroblast or leukocyte IDUA (iduronidase) activity \<10% of normal. * Participants have to be able to stand independently and walk a minimum of 5 meters in 6 minutes. * A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: * Is not a woman of childbearing potential (WOCBP). * OR * Is a WOCBP and agrees to use an acceptable contraceptive method during the intervention period and at a minimum until 7 days after the last dose of study intervention. * A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within the screening period before the first dose of study intervention. * If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. * Contraceptive/barrier method is not applicable for male participants. Exclusion Criteria: * Prior tracheostomy or bone marrow transplantation or hematopoietic stem cell transplantation. * Have a plan to undergo bone marrow transplantation or hematopoietic stem cell transplantation within half a year after enrollment. * Received an investigational drug, or device, other than Aldurazyme, within 30 days prior to study enrollment. * Received an investigational gene therapy. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.